ENXTBR:UCBPharmaceuticals
Assessing UCB (ENXTBR:UCB) Valuation After Strong 2025 Results And Pipeline Outlook
UCB (ENXTBR:UCB) drew investor attention after its 2025 earnings, reporting revenue of €7.74b, net income of €1.56b, and basic earnings per share from continuing operations of €8.20.
See our latest analysis for UCB.
The share price reaction has been mixed in the short term, with a 1 day share price return of 1.57% after results set against a 7 day share price return of an 8.62% decline. The 1 year total shareholder return of 39.89% and 5 year total shareholder return of 240.37% point to...